{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:12:14Z","timestamp":1789035134857,"version":"build-2803163510"},"reference-count":23,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Marketing authorisation is a regulatory conclusion that, on the basis of the available evidence, the medicine has a favourable benefit\u2013risk balance for a defined population and indication [...]<\/jats:p>","DOI":"10.3390\/jcm15186994","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:13:03Z","timestamp":1789031583000},"page":"6994","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse Drug Reactions: Building Drug Safety Beyond Marketing Authorisation"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7848-6600","authenticated-orcid":false,"given":"Andrej","family":"Belan\u010di\u0107","sequence":"first","affiliation":[{"name":"Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, Bra\u0107e Branchetta 20, 51000 Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Mudni\u0107","sequence":"additional","affiliation":[{"name":"Department of Basic and Clinical Pharmacology, University of Split School of Medicine, \u0160oltanska 2A, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bcp.15584","article-title":"Quo vadis (where are you going) pharmacovigilance?","volume":"89","author":"Kulkarni","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: Definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2417399","DOI":"10.1080\/20523211.2024.2417399","article-title":"Pharmacovigilance: The evolution of drug safety monitoring","volume":"17","author":"Khan","year":"2024","journal-title":"J. Pharm. Policy Pract."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Day, M.V., Munshi, R., Picard, K., and Malek, A.E. (2026). Factors Affecting Vancomycin and Piperacillin-Tazobactam-Induced Nephrotoxicity. J. Clin. Med., 15.","DOI":"10.3390\/jcm15135020"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Alshammari, T.M., Alshammari, M.K., Alosaimi, H.M., Yasmeen, A., and Syed, M.H. (2026). Proton Pump Inhibitors and Disproportionate Reporting of Acute Kidney Injury and Tubulointerstitial Nephritis: A FAERS Pharmacovigilance Study, 2020\u20132025. J. Clin. Med., 15.","DOI":"10.3390\/jcm15031298"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Saleh, T., Ramadan, M., Alsoud, A., and Al Shboul, S. (2026). Disproportionality Analysis of Hematologic Adverse Event Signals Associated with Venetoclax in Combination with Senescence-Inducing Chemotherapy. J. Clin. Med., 15.","DOI":"10.3390\/jcm15062194"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Due\u00f1as Lopez, F.C., Del Solar Moreno, Z., Aguilar-Concepci\u00f3n, D., Ruiz-Fern\u00e1ndez, C., Akatbach-Bousaid, I., Rogozina, O., Mart\u00edn-L\u00f3pez, S., Mart\u00ednez Feito, A., Gonz\u00e1lez-Mu\u00f1oz, M., and Ram\u00edrez, E. (2025). The Role of the Lymphocyte Transformation Test in Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Case Series. J. Clin. Med., 14.","DOI":"10.3390\/jcm14238596"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"K\u0131rd\u00f6k, K., Tunakan Dalg\u0131\u00e7, C., Kural, R.F., Galata, Z., Ate\u015f, \u00dc., Dizdar Canbaz, T., Ay, E., Aslan, E., Toksoy \u015eent\u00fcrk, M.\u0130., and Karaaslan Yetemen, S. (2026). Negative Test, Persistent Avoidance: Real-World Outcomes of Quinolone De-Labeling. J. Clin. Med., 15.","DOI":"10.3390\/jcm15114334"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kural, R.F., Tunakan Dalg\u0131\u00e7, C., \u00d6zeke, Y., Okan, K., Af\u015fin, S., G\u00fcm\u00fc\u015fburun, R., K\u0131rd\u00f6k, K., Galata, Z., Toksoy \u015eent\u00fcrk, M.\u0130., and Ate\u015f, \u00dc. (2026). Immediate-Type PPI Hypersensitivity as a Severe Adverse Drug Reaction: Diagnostic Challenges, Cross-Reactivity, and Real-Life Outcomes. J. Clin. Med., 15.","DOI":"10.3390\/jcm15051808"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Capinha, M., Lavrador, M., Liberato, J., Pinheiro, A., Aveiro, A., Figueiredo, I.V., and Castel-Branco, M. (2025). Drug-Induced Hyponatremia: Insights into Pharmacological Mechanisms and Clinical Practice Management. J. Clin. Med., 14.","DOI":"10.3390\/jcm14186584"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"\u017be\u0142abowski, K., Wojtysiak, K., Ratka, Z., Biedka, K., and Ch\u0142opa\u015b-Konowa\u0142ek, A. (2025). Lamotrigine Therapy: Relation Between Treatment of Bipolar Affective Disorder and Incidence of Stevens-Johnson Syndrome\u2014A Narrative Review of the Existing Literature. J. Clin. Med., 14.","DOI":"10.3390\/jcm14124103"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ko, M., Kim, K., Jang, H., Lee, S., Shin, B., Cho, B., Kim, S., and Jang, H.Y. (2025). Real-World Safety of Cyproheptadine-Based Appetite Stimulants: An Electronic Health Record-Based Retrospective Cohort Study in Adult Patients. J. Clin. Med., 15.","DOI":"10.3390\/jcm15010054"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Gandhi, A., Bhatt, N., and Parhizgar, A. (2025). Comparative Renal Safety of Tirzepatide and Semaglutide: An FDA Adverse Event Reporting System (FAERS)-Disproportionality Study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14217678"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Feszak, I.J., Brzezi\u0144ski, P., Feszak, S., Kitowska, A., Wa\u015bkow, M., Kawczak, P., and B\u0105czek, T. (2025). Isotretinoin Treatment for Acne Vulgaris: A Five-Year Retrospective Analysis of Clinical and Biochemical Adverse Effects. J. Clin. Med., 14.","DOI":"10.3390\/jcm14186473"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Belan\u010di\u0107, A., Mas, P., Mileti\u0107, L., Kova\u010di\u0107 Bytyqi, B., and Vitezi\u0107, D. (2025). Post-Marketing Safety of Spinal Muscular Atrophy Therapies: Analysis of Spontaneous Adverse Drug Reactions from EudraVigilance. J. Clin. Med., 14.","DOI":"10.3390\/jcm14093173"},{"key":"ref_16","unstructured":"(2026, August 26). Clinical Pharmacology: Adverse Drug Reactions. Available online: https:\/\/www.mdpi.com\/journal\/jcm\/special_issues\/U0EP1LK1Q7."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gkrinia, E.M.M., Belan\u010di\u0107, A., and Jankovi\u0107, S.M. (2026). Putting FAERS data into perspective: Cautionary considerations for comparative safety assessment. Eur. J. Hosp. Pharm., Epub ahead of print.","DOI":"10.1136\/ejhpharm-2026-005052"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e70007","DOI":"10.1002\/pds.70007","article-title":"PMDA Perspective on RWD\/RWE Utilization for Regulatory Purposes Including Assessment on the Impacts of Regulatory Actions and Safety Risk of a Drug at Postmarketing Stage","volume":"33","author":"Kajiyama","year":"2024","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1208\/s12248-025-01082-1","article-title":"Application of Real-World Evidence to Support FDA Regulatory Decision Making","volume":"27","author":"Khaowroongrueng","year":"2025","journal-title":"AAPS J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jaip.2020.08.002","article-title":"Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: General Concepts","volume":"8","author":"Broyles","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jclinepi.2023.08.010","article-title":"Pharmacovigilance studies without a priori hypothesis: Systematic review highlights inappropriate multiple testing correction procedures","volume":"162","author":"Gaucher","year":"2023","journal-title":"J. Clin. Epidemiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20420986251361435","article-title":"Artificial intelligence in pharmacovigilance: Advancing drug safety monitoring and regulatory integration","volume":"16","author":"Nagar","year":"2025","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/bcp.16140","article-title":"Past, present and future of drug safety: Editorial","volume":"90","author":"Rieder","year":"2024","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/6994\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:42:18Z","timestamp":1789033338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/6994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":23,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15186994"],"URL":"https:\/\/doi.org\/10.3390\/jcm15186994","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}